<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01560546</url>
  </required_header>
  <id_info>
    <org_study_id>2011-002102-73</org_study_id>
    <nct_id>NCT01560546</nct_id>
  </id_info>
  <brief_title>Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <official_title>Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM) - a Randomised, Doubleblinded and Placebocontrolled Trial of Men With Subnormal Testosterone Levels and T2DM.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marianne Andersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, placebo-controlled, double-blinded study on 40 men with type 2 DM.

      Type 2 diabetes mellitus (T2DM) is a common endocrine disorder characterized by
      hyperinsulinaemia and insulin resistance.

      Hypothesis Testosterone therapy increases lean body mass and insulin sensitivity in men with
      low normal levels of bioavailable testosterone and type 2 DM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Inadequate levels of androgens have been associated with an increased risk of
      chronic illnesses including obesity and diabetes. Moreover, testosterone treatment has been
      shown to increase lean body mass and lipid oxidation as well as insulin sensitivity in
      hypogonadal men.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lean body mass</measure>
    <time_frame>approximately three years</time_frame>
    <description>Accessed by DXA scanning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>three years</time_frame>
    <description>Euglycemic hyperinsulinaemic clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional body composition and liver fat</measure>
    <time_frame>three years</time_frame>
    <description>DXA- and MR-scans and spect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose and lipid oxidation</measure>
    <time_frame>three years</time_frame>
    <description>Indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myostatin and satellite cells</measure>
    <time_frame>8 years</time_frame>
    <description>Muscle biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>8 years</time_frame>
    <description>Hormones: Adiponectin, leptin osteoprotegerin, IGF-I, bioactive IGF-I, Urine cortisol and steroid metabolites etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>three years</time_frame>
    <description>Questionaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>three years</time_frame>
    <description>Questionaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual function</measure>
    <time_frame>Three years</time_frame>
    <description>Questionaires</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Testim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>50 mg/dose/day for 24 weeks</description>
    <arm_group_label>Testim</arm_group_label>
    <other_name>Testim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo on the skin for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male gender age 50-70

          -  Bioavailable testosterone &lt; 7,3 nmol/L

          -  Metformin treatment of T2DM for 3 months or more

        Exclusion Criteria:

          -  HbA1c &gt; 9,0 %, BMI &gt; 40 kg/m2, Haematocrit &gt; 50%,

          -  Known malignant disease, PSA &gt; 3 ug/L, Nycturia &gt; 3 times,

          -  Abnormal routine blood samples,

          -  Severe hypertension,

          -  Significant EKG-changes,

          -  Wish of parenthood,

          -  Active mental illness,

          -  former or present abuse,

          -  Severe illness of heart-, lung- or kidney,

          -  Primary or secondary hypogonadism.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne Andersen, MD, ph.d.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Department of Endocrinology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2012</study_first_submitted>
  <study_first_submitted_qc>March 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2012</study_first_posted>
  <last_update_submitted>November 13, 2013</last_update_submitted>
  <last_update_submitted_qc>November 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Marianne Andersen</investigator_full_name>
    <investigator_title>MD, ph.d.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

